These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 10194543)

  • 1. Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study.
    van Gijn R; ten Bokkel Huinink WW; Rodenhuis S; Vermorken JB; van Tellingen O; Rosing H; van Warmerdam LJ; Beijnen JH
    Anticancer Drugs; 1999 Jan; 10(1):17-23. PubMed ID: 10194543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients.
    Abigerges D; Armand JP; Chabot GG; Bruno R; Bissery MC; Bayssas M; Klink-Alakl M; Clavel M; Catimel G
    Anticancer Drugs; 1996 Feb; 7(2):166-74. PubMed ID: 8740721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors.
    Newman RA; Kim J; Newman BM; Bruno R; Bayssas M; Klink-Alaki M; Pazdur R
    Anticancer Drugs; 1999 Nov; 10(10):889-94. PubMed ID: 10630356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro.
    Eckardt JR; Burris HA; Kuhn JG; Bissery MC; Klink-Alakl M; Clark GM; Von Hoff DD
    J Natl Cancer Inst; 1994 Jan; 86(1):30-3. PubMed ID: 8271279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
    Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
    Rubin E; Wood V; Bharti A; Trites D; Lynch C; Hurwitz S; Bartel S; Levy S; Rosowsky A; Toppmeyer D
    Clin Cancer Res; 1995 Mar; 1(3):269-76. PubMed ID: 9815982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.
    Paz-Ares L; Kunka R; DeMaria D; Cassidy J; Alden M; Beranek P; Kaye S; Littlefield D; Reilly D; Depee S; Wissel P; Twelves C; O'Dwyer P
    Br J Cancer; 1998 Nov; 78(10):1329-36. PubMed ID: 9823974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule.
    Fyfe D; Price C; Langley RE; Pagonis C; Houghton J; Osborne L; Woll PJ; Gardner C; Baguley BC; Carmichael J;
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):333-7. PubMed ID: 11345650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of intoplicine, a new antitumour drug, in human whole blood and plasma by normal-phase high-performance liquid chromatography with fluorescence detection.
    van Gijn R; Rosing H; ten Bokkel Huinink WW; van Tellingen O; Vermorken JB; Liefting AJ; Bruno R; Pinedo HM; Beijnen JH
    J Chromatogr; 1993 May; 614(2):299-306. PubMed ID: 8314943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
    Poddevin B; Riou JF; Lavelle F; Pommier Y
    Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical and phase I trials of topoisomerase I inhibitors.
    Von Hoff DD; Burris HA; Eckardt J; Rothenberg M; Fields SM; Chen SF; Kuhn JG
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S41-5. PubMed ID: 8070026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
    Gerrits CJ; Creemers GJ; Schellens JH; Wissel P; Planting AS; Kunka R; Selinger K; de Boer-Dennert M; Marijnen Y; Harteveld M; Verweij J
    Br J Cancer; 1996 Mar; 73(6):744-50. PubMed ID: 8611374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.
    van Warmerdam LJ; ten Bokkel Huinink WW; Rodenhuis S; Koier I; Davies BE; Rosing H; Maes RA; Beijnen JH
    J Clin Oncol; 1995 Jul; 13(7):1768-76. PubMed ID: 7602366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
    Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
    Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.
    Riou JF; Fossé P; Nguyen CH; Larsen AK; Bissery MC; Grondard L; Saucier JM; Bisagni E; Lavelle F
    Cancer Res; 1993 Dec; 53(24):5987-93. PubMed ID: 8261412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077.
    Britten CD; Rowinsky EK; Baker SD; Weiss GR; Smith L; Stephenson J; Rothenberg M; Smetzer L; Cramer J; Collins W; Von Hoff DD; Eckhardt SG
    Clin Cancer Res; 2000 Jan; 6(1):42-9. PubMed ID: 10656430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.
    Wadler S; Makower D; Clairmont C; Lambert P; Fehn K; Sznol M
    J Clin Oncol; 2004 May; 22(9):1553-63. PubMed ID: 15117978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study.
    Takahashi S; Fujiwara Y; Nakano K; Shimizu T; Tomomatsu J; Koyama T; Ogura M; Tachibana M; Kakurai Y; Yamashita T; Sakajiri S; Yamamoto N
    Cancer Sci; 2021 Jun; 112(6):2361-2370. PubMed ID: 33686772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.